Walleye Capital
LEGN icon

Walleye Capital’s Legend Biotech LEGN Stock Holding History

Walleye Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-235,415
Closed -$4.26M – 4987
2026
Q1 		$4.26M Sell
235,415
-64,048
-21% -$1.22M 0.02% 903
2025
Q4 		$6.51M Buy
299,463
+251,037
+518% +$7.19M 0.02% 948
2025
Q3 		$1.58M Buy
48,426
+47,248
+4,011% +$1.74M 0.01% 1755
2025
Q2 		$41.8K Sell
1,178
-72,934
-98% -$2.36M ﹤0.01% 4089
2025
Q1 		$2.51M Sell
74,112
-6,328
-8% -$227K 0.01% 1263
2024
Q4 		$2.62M Buy
80,440
+77,447
+2,588% +$3.21M 0.01% 1532
2024
Q3 		$146K Sell
2,993
-131,985
-98% -$7.03M ﹤0.01% 4207
2024
Q2 		$5.98M Buy
134,978
+132,762
+5,991% +$6.12M 0.01% 1165
2024
Q1 		$124K Buy
+2,216
New +$134K ﹤0.01% 4271

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Walleye Capital's LEGN Position: Q2 2026 in Review

Walleye Capital sold out of Legend Biotech (LEGN) in Q2 2026, closing a stake of 235,415 shares — an estimated $4.26M sold.

Walleye Capital first reported a position in LEGN in Q1 2024 and held it in 9 quarters. The position peaked at $6.51M in Q4 2025. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Walleye Capital reported no remaining Legend Biotech position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 235,415 Legend Biotech shares in Q2 2026, an estimated $4.26M.
  • Walleye Capital first reported a position in Legend Biotech in Q1 2024 and held it in 9 quarters.
  • Walleye Capital's Legend Biotech position peaked at $6.51M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.